Under the agreement, Imperial College will take up the responsibility for VAL101’s late preclinical development.
The aim is to provide validation for the GeneICE clinical applications and validation for the use of GeneICE technology as a silencing tool
However, Oxford University is expected to carry out the late preclinical development of VAL201 to combat hormone refractory prostate cancer and also further indications of hormone induced unregulated growth.
All intellectual and commercial property rights from the work undertaken by both Oxford University and Imperial College will continue to be owned by ValiRx.
ValiRx CEO Satu Vainikka said they look forward to ValiRx benefiting greatly from this association and for the future successful progress and development of therapeutic medicines.